ZVRA
Zevra
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 2
stock price surged significantly
consensus rating "Strong Buy"
MACD Golden Cross
EPS Below Expectations
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About ZVRA
Zevra Therapeutics, Inc.
A specialty pharmaceutical company focused on treatments for rare central nervous system, neurodegenerative and lysosomal storage diseases
1180 Celebration Boulevard, Suite 103, Celebration, FL 34747
--
Zevra Therapeutics, Inc., was incorporated in Iowa in October 2006 and reorganized in Delaware in May 2014. The company is a rare disease company that combines science, data and patient needs to create translational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapies to people with rare diseases. With a unique, data-driven development and commercialization strategy, the company is overcoming complex drug development challenges to deliver new therapies to the rare disease community. The company has a diverse product portfolio and product candidates that include preclinical development programs, clinical-stage pipelines and commercial-stage assets. The company's team has expertise and a successful track record of advancing promising therapies that face complex clinical and regulatory challenges by balancing science and data with patient needs.
Company Financials
EPS
ZVRA has released its 2024 Q4 earnings. EPS was reported at -0.67, versus the expected -0.40, missing expectations. The chart below visualizes how ZVRA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ZVRA has released its 2024 Q4 earnings report, with revenue of 12.04M, reflecting a YoY change of -6.79%, and net profit of -35.74M, showing a YoY change of -79.67%. The Sankey diagram below clearly presents ZVRA’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available